Sign Up to like & get
recommendations!
0
Published in 2021 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics13122172
Abstract: A combination of the tyrosine kinase inhibitor—sorafenib—and the opioid analgesic—morphine—can be found in the treatment of cancer patients. Since both are substrates of P-glycoprotein (P-gp), and sorafenib is also an inhibitor of P-gp, their co-administration…
read more here.
Keywords:
pharmacokinetic drug;
sorafenib morphine;
morphine;
study ... See more keywords